2016 News
Santen, RIKEN and FBRI Announce Research Collaboration to Develop New Retinal Disease Treatments
Notice on Details of Subscription Rights to New Shares (Stock Options for Stock-Linked Remuneration)
Santen Completes Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen and University College London to collaborate on ophthalmic research and education
Santen to Grant Subscription Rights to New Shares as Stock Options for Stock-Linked Remuneration
Santen to Acquire InnFocus, Developer of MicroShunt Glaucoma Implant Device
Vekacia® (Ciclosporin 1mg/mL Eye Drops) Pivotal Trial Meets Primary and Key Secondary Endpoints
Santen Provides Update on EU Marketing Authorization Application for DE-109 (Sirolimus)
Santen Enters Licensing Agreement with Ono for FP/EP3 Dual Agonist, ONO-9054
Santen China and Chongqing Kerui Announce Collaboration to Develop New Ophthalmic Joint Venture
Santen Makes Contribution to Support the Recovery of Areas Affected by the Earthquake in Taiwan
Santen Announces Financial Result for the Third Quarter ended December 31, 2015